中国实用神经疾病杂志
中國實用神經疾病雜誌
중국실용신경질병잡지
CHINESE JOURNAL OF PRACTICAL NERVOUS DISEASES
2014年
15期
16-18
,共3页
氯氮平%金刚烷胺%帕金森病%异动症
氯氮平%金剛烷胺%帕金森病%異動癥
록담평%금강완알%파금삼병%이동증
Clozapine%Amantadine%Parkinson's disease%Dyskinesias
目的：探讨氯氮平治疗帕金森病（PD）左旋多巴诱导的异动症（levodopa-induced dyskinesias ，LID）的临床疗效。方法将42例帕金森病患者随机分为氯氮平组与金刚烷胺组，每组21例，均应用美多巴和普拉克索作为帕金森病基础治疗。经12周联合用药治疗后，以统一帕金森病评定量表（U PDRS ）各部分评分相对于基线（治疗前评分）的变化为指标评估疗效。同时监测血常规，观察患者不良反应，比较2组治疗方案的安全性。结果治疗12周后，氯氮平组和金刚烷胺组 U PDRS-Ⅳa （治疗的并发症）评分相对基线均显著下降，差异有统计学意义（P＜0.05），2组比较差异无统计学意义（P＞0.05）。氯氮平组总有效率80.9％，金刚烷胺组为85.7％（ P＞0.05）。2组不良反应发生率分别为24％、29％，差异无统计学意义（ P＞0.05）。结论氯氮平治疗帕金森病左旋多巴导致的异动症可获得较显著的近期疗效。
目的：探討氯氮平治療帕金森病（PD）左鏇多巴誘導的異動癥（levodopa-induced dyskinesias ，LID）的臨床療效。方法將42例帕金森病患者隨機分為氯氮平組與金剛烷胺組，每組21例，均應用美多巴和普拉剋索作為帕金森病基礎治療。經12週聯閤用藥治療後，以統一帕金森病評定量錶（U PDRS ）各部分評分相對于基線（治療前評分）的變化為指標評估療效。同時鑑測血常規，觀察患者不良反應，比較2組治療方案的安全性。結果治療12週後，氯氮平組和金剛烷胺組 U PDRS-Ⅳa （治療的併髮癥）評分相對基線均顯著下降，差異有統計學意義（P＜0.05），2組比較差異無統計學意義（P＞0.05）。氯氮平組總有效率80.9％，金剛烷胺組為85.7％（ P＞0.05）。2組不良反應髮生率分彆為24％、29％，差異無統計學意義（ P＞0.05）。結論氯氮平治療帕金森病左鏇多巴導緻的異動癥可穫得較顯著的近期療效。
목적：탐토록담평치료파금삼병（PD）좌선다파유도적이동증（levodopa-induced dyskinesias ，LID）적림상료효。방법장42례파금삼병환자수궤분위록담평조여금강완알조，매조21례，균응용미다파화보랍극색작위파금삼병기출치료。경12주연합용약치료후，이통일파금삼병평정량표（U PDRS ）각부분평분상대우기선（치료전평분）적변화위지표평고료효。동시감측혈상규，관찰환자불량반응，비교2조치료방안적안전성。결과치료12주후，록담평조화금강완알조 U PDRS-Ⅳa （치료적병발증）평분상대기선균현저하강，차이유통계학의의（P＜0.05），2조비교차이무통계학의의（P＞0.05）。록담평조총유효솔80.9％，금강완알조위85.7％（ P＞0.05）。2조불량반응발생솔분별위24％、29％，차이무통계학의의（ P＞0.05）。결론록담평치료파금삼병좌선다파도치적이동증가획득교현저적근기료효。
Objective To investigate the efficacy ,safety and tolerability of clozapine in Parkinson's disease patients suffer-ing from dyskinesias .Methods Included in the present study were 40 PD patients with Parkinson's disease and dyskinesias who received clozapine or amantadine as an adjunct to levodopa and pramipexole for 12 weeks in our institute .The outcome meas-ures were changes in the unified Parkinson's disease rating scale part Ⅳa (UPDRS-Ⅳa) ,part Ⅳb (motor fluctuations ) ,and part Ⅲ (motor function) during each treatment period .The safety and tolerability were assessed on the basis of side effects and blood pressure .Results UPDRS-Ⅳa was improved to a significantly greater degree in patients of both groups treated for two weeks compared with those of before treatment (P<0 .01) .However ,UPDRS-Ⅳa of two groups were no difference after two weeks'treatment(P>0 .05) .There were no significant effects on UPDRS-Ⅳb or Ⅲ scores between two groups after treatment (P>0 .05) .No significant difference was found between the clozapine and amantadine groups in terms of adverse events (P>0 .05) .Conclusion Results from the present study demonstrated that clozapine exhibited efficacious effects on dyskinesias in about 80% patients as amantadine did at least with short-term use .Its side effect of leukopenia is acceptable under strict mo-nito ring.
